Duchenne muscular dystrophy
Conditions
Interventions
Group A:Perindopril
Group B:metoprolol
Group C:Perindopril and metoprolol
Sponsors
West China Second University Hospital, Sichuan University
Eligibility
Sex/Gender
Male
Age
1 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. The patients with DMD were suspected to have progressive muscular dystrophy related diseases, and the mutations or deletions of DMD gene were found by further gene detection. 2. Patients who have received standard corticosteroid shock therapy but have not been treated with Angiotension, spironolactone, ARB and beta - blocker. 3. The renal function of the patients younger than 18 years old, male, was normal before MR examination (the clearance rate of serum creatinine was more than 120 mmol / L). 4. The patients who were assessed by Polaris scale and MRI of legs before the study were selected. The preliminary assessment showed that the skeletal muscle was obviously involved and the muscle strength was weakened. 5. In patients without contraindications of MR examination, myocardial abnormalities were found by T1 mapping and delayed enhancement, but the LVEF value was in the normal range. 6. Patients who understand the potential risks / benefits, agree to participate in the study, understand the study procedures, agree to complete the study follow-up and comply with the requirements of the study protocol.
Exclusion criteria
Exclusion criteria: 1. Patients with congenital heart disease and primary cardiomyopathy. 2. Patients with serious arrhythmia, frequent atrial fibrillation and serious image quality artifacts. 3. Patients with drug contraindications for the treatment of Angiotension inhibitors or spironolactones. 4. Patients who have participated in drug or biological preparation trials that may confuse the results of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Medical Research Council Scale;Three functional tasks;cardiac function;Value of T1 mapping;Late delayed enhancement;Grading of leg steatosis;NYHA classification; | — |
Secondary
| Measure | Time frame |
|---|---|
| Markers of myocardial injury;electrocardiogram;myocardial perfusion;Myocardial enzyme; | — |
Countries
China
Contacts
Public ContactYingkun Guo
West China Second Hospital of Sichuan University
Outcome results
None listed